Investigational BPH drug shows no adverse events in phase II study
A third interim safety analysis of an ongoing multicenter phase II trial of NX-1207, for the treatment of BPH, has revealed no serious side effects, according to Nymox Pharmaceutical Corp., the drug's manufacturer.
A third interim safety analysis of an ongoing multicenter phase II trial of NX-1207, for the treatment of BPH, has revealed no serious side effects, according to Nymox Pharmaceutical Corp., the drug’s manufacturer.
In the completed trials to date, patients treated with the therapy showed statistically significant overall mean symptom improvement and shrinkage in prostate size. There were no serious adverse events, and patients who were followed up to 2 years post-treatment showed even further statistically significant symptom improvement, the company said.
